What is it about?
A safe and dissolvable controlled release system was programmed to deliver the glaucoma drug, brimonidine tartrate (BT) for one month. This delivery system was characterized and confirmed to perform as intended in design. One dose of the BT release system in a model of glaucoma in rabbits was proven to be equivalent (IOP pressure drop) to twice daily eye drops for an entire month (56 administrations).
Featured Image
Why is it important?
Glaucoma is a leading cause of blindness, which is exacerbated by extremely low compliance rates of patients, who fail to correctly self-administer multiple eye drops daily. Controlled release systems that can correctly delivery treatment with fewer administrations and less drug could be transformative to treating glaucoma. This work was featured in the Wall Street Journal, August 4th, 2014 edition: http://online.wsj.com/articles/needle-treatment-for-glaucoma-shows-promise-1407193884
Read the Original
This page is a summary of: 28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres, Experimental Eye Research, August 2014, Elsevier,
DOI: 10.1016/j.exer.2014.06.013.
You can read the full text:
Resources
Contributors
The following have contributed to this page
